Quantum BioPharma Ltd. Comprehensive Income Attributable To Noncontrolling Interests
Quantum BioPharma Ltd. (QNTM) reported Comprehensive Income Attributable To Noncontrolling Interests of -$781.55 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Income Statement › Unrealized Gains
ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests · last filed 2026-03-26
- Quantum BioPharma Ltd. comprehensive income attributable to noncontrolling interests for the quarter ending 2025-12-31 was -$676.57K.
- Quantum BioPharma Ltd. comprehensive income attributable to noncontrolling interests for the quarter ending 2025-09-30 was $571.43K.
- Quantum BioPharma Ltd. comprehensive income attributable to noncontrolling interests for the quarter ending 2025-06-30 was -$513.26K.
- Quantum BioPharma Ltd. comprehensive income attributable to noncontrolling interests for the quarter ending 2025-03-31 was -$163.16K.
| Period end | Comprehensive Income Attributable To Noncontrolling Interests 3 month | Comprehensive Income Attributable To Noncontrolling Interests 6 month | Comprehensive Income Attributable To Noncontrolling Interests 9 month | Comprehensive Income Attributable To Noncontrolling Interests 12 month | Comprehensive Income Attributable To Noncontrolling Interests 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$676.57K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$105.14K derived: sum of 2 quarters · filed 2026-03-26 | -$618.40K derived: sum of 3 quarters · filed 2026-03-26 | -$781.55K 20-F · filed 2026-03-26 | |
| 2025-09-30 | $571.43K 6-K · filed 2025-11-06 | $58.17K derived: sum of 2 quarters · filed 2025-11-06 | -$104.99K 6-K · filed 2025-11-06 | -$201.00K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2025-06-30 | -$513.26K 6-K · filed 2025-08-07 | -$676.42K 6-K · filed 2025-08-07 | -$772.43K derived: sum of 3 quarters · filed 2026-03-26 | -$960.59K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2025-03-31 | -$163.16K 6-K/A · filed 2025-06-16 | -$259.17K derived: sum of 2 quarters · filed 2026-03-26 | -$447.33K derived: sum of 3 quarters · filed 2026-03-26 | -$687.91K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2024-12-31 | -$96.02K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$284.17K derived: sum of 2 quarters · filed 2026-03-26 | -$524.75K derived: sum of 3 quarters · filed 2026-03-26 | -$712.80K 20-F · filed 2026-03-26 | |
| 2024-09-30 | -$188.16K 6-K · filed 2025-11-06 | -$428.74K derived: sum of 2 quarters · filed 2025-11-06 | -$616.79K 6-K · filed 2025-11-06 | ||
| 2024-06-30 | -$240.58K 6-K · filed 2025-08-07 | -$428.63K 6-K · filed 2025-08-07 | |||
| 2024-03-31 | -$188.05K 6-K/A · filed 2025-06-16 | ||||
| 2023-12-31 | -$328.41K 20-F · filed 2026-03-26 | $328.41K 20-F · filed 2024-04-02 | |||
| 2023-06-30 | $0.00 6-K/A · filed 2024-08-19 | $0.00 6-K/A · filed 2024-08-19 | |||
| 2022-12-31 | $0.00 20-F/A · filed 2025-03-31 | ||||
| 2021-12-31 | $0.00 20-F · filed 2024-04-02 |